JP6723264B2 - Ｐｅｔイメージング剤 - Google Patents
Ｐｅｔイメージング剤 Download PDFInfo
- Publication number
- JP6723264B2 JP6723264B2 JP2017555866A JP2017555866A JP6723264B2 JP 6723264 B2 JP6723264 B2 JP 6723264B2 JP 2017555866 A JP2017555866 A JP 2017555866A JP 2017555866 A JP2017555866 A JP 2017555866A JP 6723264 B2 JP6723264 B2 JP 6723264B2
- Authority
- JP
- Japan
- Prior art keywords
- methyl
- acceptable salt
- pharmaceutically acceptable
- compound
- autotaxin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 238000012879 PET imaging Methods 0.000 title claims description 4
- 239000012216 imaging agent Substances 0.000 title description 3
- 150000001875 compounds Chemical class 0.000 claims description 94
- 102100021977 Ectonucleotide pyrophosphatase/phosphodiesterase family member 2 Human genes 0.000 claims description 56
- 108050004000 Ectonucleotide pyrophosphatase/phosphodiesterase family member 2 Proteins 0.000 claims description 56
- 238000000034 method Methods 0.000 claims description 31
- 239000000203 mixture Substances 0.000 claims description 29
- 150000003839 salts Chemical class 0.000 claims description 27
- 238000003384 imaging method Methods 0.000 claims description 25
- 238000002603 single-photon emission computed tomography Methods 0.000 claims description 21
- 238000001727 in vivo Methods 0.000 claims description 15
- 239000003446 ligand Substances 0.000 claims description 9
- 239000003795 chemical substances by application Substances 0.000 claims description 7
- 229910052736 halogen Inorganic materials 0.000 claims description 7
- 230000008859 change Effects 0.000 claims description 5
- 125000005843 halogen group Chemical group 0.000 claims description 5
- 239000000758 substrate Substances 0.000 claims description 4
- 125000002971 oxazolyl group Chemical group 0.000 claims description 3
- 125000004076 pyridyl group Chemical group 0.000 claims description 3
- 230000005258 radioactive decay Effects 0.000 claims description 3
- 125000001424 substituent group Chemical group 0.000 claims description 3
- 125000004429 atom Chemical group 0.000 claims description 2
- 238000011260 co-administration Methods 0.000 claims description 2
- 238000012831 peritoneal equilibrium test Methods 0.000 claims 3
- 238000012636 positron electron tomography Methods 0.000 claims 3
- 238000012877 positron emission topography Methods 0.000 claims 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 74
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 39
- 239000000243 solution Substances 0.000 description 35
- 235000019439 ethyl acetate Nutrition 0.000 description 34
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 33
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 30
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 30
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 29
- 239000011541 reaction mixture Substances 0.000 description 26
- 238000002600 positron emission tomography Methods 0.000 description 24
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 22
- 239000012071 phase Substances 0.000 description 21
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 20
- 238000004458 analytical method Methods 0.000 description 20
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 20
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 18
- -1 choline phosphates Chemical class 0.000 description 18
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 17
- 239000012043 crude product Substances 0.000 description 17
- 238000005481 NMR spectroscopy Methods 0.000 description 15
- 239000012267 brine Substances 0.000 description 15
- 238000004128 high performance liquid chromatography Methods 0.000 description 15
- 239000000047 product Substances 0.000 description 15
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 15
- 239000012044 organic layer Substances 0.000 description 14
- 239000007787 solid Substances 0.000 description 14
- 239000002904 solvent Substances 0.000 description 13
- AFABGHUZZDYHJO-UHFFFAOYSA-N 2-Methylpentane Chemical compound CCCC(C)C AFABGHUZZDYHJO-UHFFFAOYSA-N 0.000 description 12
- HGINCPLSRVDWNT-UHFFFAOYSA-N Acrolein Chemical compound C=CC=O HGINCPLSRVDWNT-UHFFFAOYSA-N 0.000 description 12
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 11
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 11
- 239000003921 oil Substances 0.000 description 11
- 235000019198 oils Nutrition 0.000 description 11
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 10
- 235000019253 formic acid Nutrition 0.000 description 10
- KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 10
- 206010028980 Neoplasm Diseases 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- 239000010410 layer Substances 0.000 description 9
- 239000003643 water by type Substances 0.000 description 9
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 8
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 8
- 230000015572 biosynthetic process Effects 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 229910052739 hydrogen Inorganic materials 0.000 description 8
- 238000003786 synthesis reaction Methods 0.000 description 8
- 239000003814 drug Substances 0.000 description 7
- 229920006395 saturated elastomer Polymers 0.000 description 7
- DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Substances OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 7
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 6
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 6
- 108090000790 Enzymes Proteins 0.000 description 6
- 206010016654 Fibrosis Diseases 0.000 description 6
- 239000007864 aqueous solution Substances 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 239000000706 filtrate Substances 0.000 description 6
- 238000001914 filtration Methods 0.000 description 6
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 6
- 239000002243 precursor Substances 0.000 description 6
- 230000002285 radioactive effect Effects 0.000 description 6
- 239000000700 radioactive tracer Substances 0.000 description 6
- 230000002829 reductive effect Effects 0.000 description 6
- 238000011282 treatment Methods 0.000 description 6
- WRGQSWVCFNIUNZ-GDCKJWNLSA-N 1-oleoyl-sn-glycerol 3-phosphate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](O)COP(O)(O)=O WRGQSWVCFNIUNZ-GDCKJWNLSA-N 0.000 description 5
- BVDPWLLSIMCFHH-FVOPLDGLSA-N C[C@@H]1CNCCN1C(=O)\C=C\c1ccc(Cl)cc1Cn1nnc(C)n1 Chemical compound C[C@@H]1CNCCN1C(=O)\C=C\c1ccc(Cl)cc1Cn1nnc(C)n1 BVDPWLLSIMCFHH-FVOPLDGLSA-N 0.000 description 5
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 5
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 5
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 5
- 201000011510 cancer Diseases 0.000 description 5
- 238000001514 detection method Methods 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 238000003818 flash chromatography Methods 0.000 description 5
- 150000002367 halogens Chemical group 0.000 description 5
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 5
- 238000000746 purification Methods 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- VSHFOMAWJOVMNJ-KZJSRBBCSA-N (E)-3-[4-chloro-2-[(5-methyltetrazol-2-yl)methyl]phenyl]-1-[(2R)-4-[(5-hydroxypyridin-2-yl)methyl]-2-methylpiperazin-1-yl]prop-2-en-1-one Chemical compound ClC1=CC(=C(C=C1)/C=C/C(=O)N1[C@@H](CN(CC1)CC1=NC=C(C=C1)O)C)CN1N=C(N=N1)C VSHFOMAWJOVMNJ-KZJSRBBCSA-N 0.000 description 4
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 4
- 235000019502 Orange oil Nutrition 0.000 description 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- 238000009826 distribution Methods 0.000 description 4
- 239000003480 eluent Substances 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 230000004761 fibrosis Effects 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 230000014759 maintenance of location Effects 0.000 description 4
- 239000010502 orange oil Substances 0.000 description 4
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 238000002953 preparative HPLC Methods 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 238000001959 radiotherapy Methods 0.000 description 4
- FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- XNRDLSNSMTUXBV-UHFFFAOYSA-N 2-fluoroethyl 4-methylbenzenesulfonate Chemical compound CC1=CC=C(S(=O)(=O)OCCF)C=C1 XNRDLSNSMTUXBV-UHFFFAOYSA-N 0.000 description 3
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 3
- KQVWHUMWDUXYCB-UHFFFAOYSA-N 5-[2-(2-fluoroethoxy)ethoxy]pyridine-2-carbaldehyde Chemical compound FCCOCCOC=1C=CC(=NC=1)C=O KQVWHUMWDUXYCB-UHFFFAOYSA-N 0.000 description 3
- XZGLNCKSNVGDNX-UHFFFAOYSA-N 5-methyl-2h-tetrazole Chemical compound CC=1N=NNN=1 XZGLNCKSNVGDNX-UHFFFAOYSA-N 0.000 description 3
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 3
- 208000003251 Pruritus Diseases 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- KRHYYFGTRYWZRS-BJUDXGSMSA-N ac1l2y5h Chemical compound [18FH] KRHYYFGTRYWZRS-BJUDXGSMSA-N 0.000 description 3
- 229910021529 ammonia Inorganic materials 0.000 description 3
- 229910052786 argon Inorganic materials 0.000 description 3
- JFDZBHWFFUWGJE-UHFFFAOYSA-N benzonitrile Chemical compound N#CC1=CC=CC=C1 JFDZBHWFFUWGJE-UHFFFAOYSA-N 0.000 description 3
- 229960001231 choline Drugs 0.000 description 3
- 239000012230 colorless oil Substances 0.000 description 3
- 238000002591 computed tomography Methods 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- VRZVPALEJCLXPR-UHFFFAOYSA-N ethyl 4-methylbenzenesulfonate Chemical compound CCOS(=O)(=O)C1=CC=C(C)C=C1 VRZVPALEJCLXPR-UHFFFAOYSA-N 0.000 description 3
- 230000005484 gravity Effects 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 238000009206 nuclear medicine Methods 0.000 description 3
- 125000003729 nucleotide group Chemical group 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- PKYCWFICOKSIHZ-UHFFFAOYSA-N 1-(3,7-dihydroxyphenoxazin-10-yl)ethanone Chemical compound OC1=CC=C2N(C(=O)C)C3=CC=C(O)C=C3OC2=C1 PKYCWFICOKSIHZ-UHFFFAOYSA-N 0.000 description 2
- RYCNUMLMNKHWPZ-SNVBAGLBSA-N 1-acetyl-sn-glycero-3-phosphocholine Chemical compound CC(=O)OC[C@@H](O)COP([O-])(=O)OCC[N+](C)(C)C RYCNUMLMNKHWPZ-SNVBAGLBSA-N 0.000 description 2
- IUXBJIIDYVLKDO-UHFFFAOYSA-N 2-(fluoromethyl)-1,3-oxazole-4-carbaldehyde Chemical compound FCC1=NC(C=O)=CO1 IUXBJIIDYVLKDO-UHFFFAOYSA-N 0.000 description 2
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 2
- HSODMUBHOXGNNQ-UHFFFAOYSA-N 5-hydroxypyridine-2-carbaldehyde Chemical compound OC1=CC=C(C=O)N=C1 HSODMUBHOXGNNQ-UHFFFAOYSA-N 0.000 description 2
- 101100225890 Aplysia californica ENPP gene Proteins 0.000 description 2
- 206010008635 Cholestasis Diseases 0.000 description 2
- 108010000659 Choline oxidase Proteins 0.000 description 2
- YPHODNOCCQTSJS-MWSHLJEDSA-N ClC1=CC(=C(C=C1)/C=C/C(=O)N1[C@@H](CN(CC1)CC1=NC=C(C=C1)OCCOCC[18F])C)CN1N=C(N=N1)C Chemical compound ClC1=CC(=C(C=C1)/C=C/C(=O)N1[C@@H](CN(CC1)CC1=NC=C(C=C1)OCCOCC[18F])C)CN1N=C(N=N1)C YPHODNOCCQTSJS-MWSHLJEDSA-N 0.000 description 2
- FMGIUSJUWXCWRE-PITBZFJWSA-N ClC1=CC(=C(C=C1)/C=C/C(=O)N1[C@@H](CN(CC1)CC1=NC=C(C=C1)OCC[18F])C)CN1N=C(N=N1)C Chemical compound ClC1=CC(=C(C=C1)/C=C/C(=O)N1[C@@H](CN(CC1)CC1=NC=C(C=C1)OCC[18F])C)CN1N=C(N=N1)C FMGIUSJUWXCWRE-PITBZFJWSA-N 0.000 description 2
- ZFDPMADTMPVSDC-UHFFFAOYSA-M ClC1=CC(=C(C=C[Mg]Br)C=C1)CN1N=C(N=N1)C Chemical compound ClC1=CC(=C(C=C[Mg]Br)C=C1)CN1N=C(N=N1)C ZFDPMADTMPVSDC-UHFFFAOYSA-M 0.000 description 2
- 206010061818 Disease progression Diseases 0.000 description 2
- JIGUQPWFLRLWPJ-UHFFFAOYSA-N Ethyl acrylate Chemical compound CCOC(=O)C=C JIGUQPWFLRLWPJ-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 239000012981 Hank's balanced salt solution Substances 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 108090001050 Phosphoric Diester Hydrolases Proteins 0.000 description 2
- 102000004861 Phosphoric Diester Hydrolases Human genes 0.000 description 2
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 2
- WFDIJRYMOXRFFG-UHFFFAOYSA-N acetic acid anhydride Natural products CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 2
- 108010022198 alkylglycerophosphoethanolamine phosphodiesterase Proteins 0.000 description 2
- 238000000376 autoradiography Methods 0.000 description 2
- 229940077388 benzenesulfonate Drugs 0.000 description 2
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 2
- 229910000024 caesium carbonate Inorganic materials 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 239000003054 catalyst Substances 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 231100000359 cholestasis Toxicity 0.000 description 2
- 230000007870 cholestasis Effects 0.000 description 2
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 2
- 230000007882 cirrhosis Effects 0.000 description 2
- 208000019425 cirrhosis of liver Diseases 0.000 description 2
- 239000000032 diagnostic agent Substances 0.000 description 2
- 230000005750 disease progression Effects 0.000 description 2
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 2
- KRHYYFGTRYWZRS-BJUDXGSMSA-M fluorine-18(1-) Chemical compound [18F-] KRHYYFGTRYWZRS-BJUDXGSMSA-M 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 208000017169 kidney disease Diseases 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 208000004296 neuralgia Diseases 0.000 description 2
- 208000021722 neuropathic pain Diseases 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 229910052763 palladium Inorganic materials 0.000 description 2
- PNJWIWWMYCMZRO-UHFFFAOYSA-N pent‐4‐en‐2‐one Natural products CC(=O)CC=C PNJWIWWMYCMZRO-UHFFFAOYSA-N 0.000 description 2
- 230000035479 physiological effects, processes and functions Effects 0.000 description 2
- 229910000027 potassium carbonate Inorganic materials 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 230000003248 secreting effect Effects 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- 238000010898 silica gel chromatography Methods 0.000 description 2
- 239000002002 slurry Substances 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- 229910052938 sodium sulfate Inorganic materials 0.000 description 2
- 235000011152 sodium sulphate Nutrition 0.000 description 2
- 239000012321 sodium triacetoxyborohydride Substances 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- FMLPQHJYUZTHQS-MRVPVSSYSA-N tert-butyl (3r)-3-methylpiperazine-1-carboxylate Chemical compound C[C@@H]1CN(C(=O)OC(C)(C)C)CCN1 FMLPQHJYUZTHQS-MRVPVSSYSA-N 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- COIOYMYWGDAQPM-UHFFFAOYSA-N tris(2-methylphenyl)phosphane Chemical compound CC1=CC=CC=C1P(C=1C(=CC=CC=1)C)C1=CC=CC=C1C COIOYMYWGDAQPM-UHFFFAOYSA-N 0.000 description 2
- 229910052722 tritium Inorganic materials 0.000 description 2
- XYFIZEAYYHLECQ-LLVKDONJSA-N (3R)-1-[[5-(2-fluoroethoxy)pyridin-2-yl]methyl]-3-methylpiperazine Chemical compound FCCOC=1C=CC(=NC=1)CN1C[C@H](NCC1)C XYFIZEAYYHLECQ-LLVKDONJSA-N 0.000 description 1
- ZRHLDWFGCVUKKP-CSPWOOARSA-N (E)-1-[(2R)-4-[[2-(fluoromethyl)-1,3-oxazol-4-yl]methyl]-2-methylpiperazin-1-yl]-3-[2-[(5-methyltetrazol-2-yl)methyl]-4-(trifluoromethyl)phenyl]prop-2-en-1-one Chemical compound FCC=1OC=C(N=1)CN1C[C@H](N(CC1)C(\C=C\C1=C(C=C(C=C1)C(F)(F)F)CN1N=C(N=N1)C)=O)C ZRHLDWFGCVUKKP-CSPWOOARSA-N 0.000 description 1
- VMVHSMXBBFOLMJ-SBLNNXNXSA-N (E)-1-[(2R)-4-[[5-(2-fluoroethoxy)pyridin-2-yl]methyl]-2-methylpiperazin-1-yl]-3-[2-[(5-methyltetrazol-2-yl)methyl]-4-(trifluoromethyl)phenyl]prop-2-en-1-one Chemical compound FCCOC=1C=CC(=NC=1)CN1C[C@H](N(CC1)C(\C=C\C1=C(C=C(C=C1)C(F)(F)F)CN1N=C(N=N1)C)=O)C VMVHSMXBBFOLMJ-SBLNNXNXSA-N 0.000 description 1
- WTJMCLJURORRGF-RQFVKHKJSA-N (E)-1-[(2R)-4-[[5-(2-fluoroethoxy)pyridin-2-yl]methyl]-2-methylpiperazin-1-yl]-3-[2-[(5-methyltetrazol-2-yl)methyl]-4-tri(propan-2-yl)silyloxyphenyl]prop-2-en-1-one Chemical compound FCCOC=1C=CC(=NC=1)CN1C[C@H](N(CC1)C(\C=C\C1=C(C=C(C=C1)O[Si](C(C)C)(C(C)C)C(C)C)CN1N=C(N=N1)C)=O)C WTJMCLJURORRGF-RQFVKHKJSA-N 0.000 description 1
- WEZNLVXKPJTWLX-SBLNNXNXSA-N (E)-1-[(2R)-4-[[5-(2-fluoroethoxy)pyridin-2-yl]methyl]-2-methylpiperazin-1-yl]-3-[4-hydroxy-2-[(5-methyltetrazol-2-yl)methyl]phenyl]prop-2-en-1-one Chemical compound FCCOC=1C=CC(=NC=1)CN1C[C@H](N(CC1)C(\C=C\C1=C(C=C(C=C1)O)CN1N=C(N=N1)C)=O)C WEZNLVXKPJTWLX-SBLNNXNXSA-N 0.000 description 1
- GWWNQZJFLABKDV-SBLNNXNXSA-N (E)-1-[(2R)-4-[[5-(2-fluoroethoxy)pyridin-2-yl]methyl]-2-methylpiperazin-1-yl]-3-[4-iodo-2-[(5-methyltetrazol-2-yl)methyl]phenyl]prop-2-en-1-one Chemical compound FCCOC=1C=CC(=NC=1)CN1C[C@H](N(CC1)C(\C=C\C1=C(C=C(C=C1)I)CN1N=C(N=N1)C)=O)C GWWNQZJFLABKDV-SBLNNXNXSA-N 0.000 description 1
- BGSINKSGXAZXTN-BTZGUFSASA-N (E)-1-[(2R)-4-[[5-[2-(2-fluoroethoxy)ethoxy]pyridin-2-yl]methyl]-2-methylpiperazin-1-yl]-3-[2-[(5-methyltetrazol-2-yl)methyl]-4-(trifluoromethyl)phenyl]prop-2-en-1-one Chemical compound FCCOCCOC=1C=CC(=NC=1)CN1C[C@H](N(CC1)C(\C=C\C1=C(C=C(C=C1)C(F)(F)F)CN1N=C(N=N1)C)=O)C BGSINKSGXAZXTN-BTZGUFSASA-N 0.000 description 1
- YPHODNOCCQTSJS-BTZGUFSASA-N (E)-3-[4-chloro-2-[(5-methyltetrazol-2-yl)methyl]phenyl]-1-[(2R)-4-[[5-[2-(2-fluoroethoxy)ethoxy]pyridin-2-yl]methyl]-2-methylpiperazin-1-yl]prop-2-en-1-one Chemical compound ClC1=CC(=C(C=C1)/C=C/C(=O)N1[C@@H](CN(CC1)CC1=NC=C(C=C1)OCCOCCF)C)CN1N=C(N=N1)C YPHODNOCCQTSJS-BTZGUFSASA-N 0.000 description 1
- JBCFJMYPJJWIRG-UHFFFAOYSA-N 1,3-oxazole-4-carboxylic acid Chemical compound OC(=O)C1=COC=N1 JBCFJMYPJJWIRG-UHFFFAOYSA-N 0.000 description 1
- YAMUFBLWGFFICM-PTGWMXDISA-N 1-O-oleoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](O)COP([O-])(=O)OCC[N+](C)(C)C YAMUFBLWGFFICM-PTGWMXDISA-N 0.000 description 1
- KYWZZLHFJPTLOH-GOSISDBHSA-N 1-[(2R)-4-[[5-(2-fluoroethoxy)pyridin-2-yl]methyl]-2-methylpiperazin-1-yl]-3-[2-[(5-methyltetrazol-2-yl)methyl]-4-(trifluoromethyl)phenyl]propan-1-one Chemical compound FCCOC=1C=CC(=NC=1)CN1C[C@H](N(CC1)C(CCC1=C(C=C(C=C1)C(F)(F)F)CN1N=C(N=N1)C)=O)C KYWZZLHFJPTLOH-GOSISDBHSA-N 0.000 description 1
- KUBWJGWIWGGEPZ-UHFFFAOYSA-N 1-[amino(ethoxy)phosphoryl]oxy-4-nitrobenzene Chemical compound CCOP(N)(=O)OC1=CC=C([N+]([O-])=O)C=C1 KUBWJGWIWGGEPZ-UHFFFAOYSA-N 0.000 description 1
- TXJHPBWTPBYLFP-UHFFFAOYSA-N 1-bromo-2-(bromomethyl)-4-(trifluoromethyl)benzene Chemical compound FC(F)(F)C1=CC=C(Br)C(CBr)=C1 TXJHPBWTPBYLFP-UHFFFAOYSA-N 0.000 description 1
- UTKGZXVMMFBCJC-UHFFFAOYSA-N 1-bromo-2-(bromomethyl)-4-chlorobenzene Chemical compound ClC1=CC=C(Br)C(CBr)=C1 UTKGZXVMMFBCJC-UHFFFAOYSA-N 0.000 description 1
- JTLAIKFGRHDNQM-UHFFFAOYSA-N 1-bromo-2-fluoroethane Chemical compound FCCBr JTLAIKFGRHDNQM-UHFFFAOYSA-N 0.000 description 1
- LECMBPWEOVZHKN-UHFFFAOYSA-N 2-(2-chloroethoxy)ethanol Chemical compound OCCOCCCl LECMBPWEOVZHKN-UHFFFAOYSA-N 0.000 description 1
- LZIPBJBQQPZLOR-UHFFFAOYSA-N 2-(4-methylphenyl)sulfonyloxyethyl 4-methylbenzenesulfonate Chemical compound C1=CC(C)=CC=C1S(=O)(=O)OCCOS(=O)(=O)C1=CC=C(C)C=C1 LZIPBJBQQPZLOR-UHFFFAOYSA-N 0.000 description 1
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 1
- VWMLAWGIWVZGOP-UHFFFAOYSA-N 2-[2-(6-formylpyridin-3-yl)oxyethoxy]ethyl 4-methylbenzenesulfonate Chemical compound CC1=CC=C(C=C1)S(=O)(=O)OCCOCCOC=1C=NC(=CC=1)C=O VWMLAWGIWVZGOP-UHFFFAOYSA-N 0.000 description 1
- SZIYTAMIJASONE-WQZBXLAZSA-N 2-[2-[6-[[(3R)-4-[(E)-3-[4-chloro-2-[(5-methyltetrazol-2-yl)methyl]phenyl]prop-2-enoyl]-3-methylpiperazin-1-yl]methyl]pyridin-3-yl]oxyethoxy]ethyl 4-methylbenzenesulfonate Chemical compound CC1=CC=C(C=C1)S(=O)(=O)OCCOCCOC=1C=NC(=CC=1)CN1C[C@H](N(CC1)C(\C=C\C1=C(C=C(C=C1)Cl)CN1N=C(N=N1)C)=O)C SZIYTAMIJASONE-WQZBXLAZSA-N 0.000 description 1
- BOVAXIIRAHYORF-SNAWJCMRSA-N 2-[[2-[(E)-2-bromoethenyl]-5-chlorophenyl]methyl]-5-methyltetrazole Chemical compound Br/C=C/C1=C(CN2N=C(N=N2)C)C=C(C=C1)Cl BOVAXIIRAHYORF-SNAWJCMRSA-N 0.000 description 1
- AUFVJZSDSXXFOI-UHFFFAOYSA-N 2.2.2-cryptand Chemical compound C1COCCOCCN2CCOCCOCCN1CCOCCOCC2 AUFVJZSDSXXFOI-UHFFFAOYSA-N 0.000 description 1
- GXCNGJIYCCOIES-UHFFFAOYSA-N 3-(2-fluoroethoxy)pyridine Chemical compound FCCOC1=CC=CN=C1 GXCNGJIYCCOIES-UHFFFAOYSA-N 0.000 description 1
- NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 1
- YYROPELSRYBVMQ-UHFFFAOYSA-N 4-toluenesulfonyl chloride Chemical compound CC1=CC=C(S(Cl)(=O)=O)C=C1 YYROPELSRYBVMQ-UHFFFAOYSA-N 0.000 description 1
- BBAUJIOKAIMWJS-UHFFFAOYSA-N 5-[2-(2-fluoroethoxy)ethoxy]-2-methyl-1-oxidopyridin-1-ium Chemical compound FCCOCCOC=1C=CC(=[N+](C=1)[O-])C BBAUJIOKAIMWJS-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 1
- 238000006596 Alder-ene reaction Methods 0.000 description 1
- 241001120493 Arene Species 0.000 description 1
- PNJTYWMXDYVAII-UHFFFAOYSA-N BrC=1C=C(O[Si](C(C)C)(C(C)C)C(C)C)C=CC=1CBr Chemical compound BrC=1C=C(O[Si](C(C)C)(C(C)C)C(C)C)C=CC=1CBr PNJTYWMXDYVAII-UHFFFAOYSA-N 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- ZXJGRGFBHUTWAW-UHFFFAOYSA-N CC1=CC=C(C=N1)O.CC1=CC=C(C=N1)OCCOCCO Chemical compound CC1=CC=C(C=N1)O.CC1=CC=C(C=N1)OCCOCCO ZXJGRGFBHUTWAW-UHFFFAOYSA-N 0.000 description 1
- SIAXNAVZCNOESK-FVOPLDGLSA-N CC=1N=NN(N1)CC1=C(C=CC(=C1)C(F)(F)F)/C=C/C(=O)N1[C@@H](CNCC1)C Chemical compound CC=1N=NN(N1)CC1=C(C=CC(=C1)C(F)(F)F)/C=C/C(=O)N1[C@@H](CNCC1)C SIAXNAVZCNOESK-FVOPLDGLSA-N 0.000 description 1
- XSTFWVBTWCRGNB-UHFFFAOYSA-N CC=1N=NNN1.BrC1=C(CN2N=C(N=N2)C)C=C(C=C1)Cl Chemical compound CC=1N=NNN1.BrC1=C(CN2N=C(N=N2)C)C=C(C=C1)Cl XSTFWVBTWCRGNB-UHFFFAOYSA-N 0.000 description 1
- YPYHGEGQZFUBNQ-MNDMWVCDSA-N C[C@@H]1CN(CC(=O)OC(C)(C)C)CCN1C(=O)\C=C\c1ccc(C(F)(F)F)cc1Cn1nnc(C)n1 Chemical compound C[C@@H]1CN(CC(=O)OC(C)(C)C)CCN1C(=O)\C=C\c1ccc(C(F)(F)F)cc1Cn1nnc(C)n1 YPYHGEGQZFUBNQ-MNDMWVCDSA-N 0.000 description 1
- VDGCFTQOYQKIFX-UHFFFAOYSA-N Cc1nnn(Cc2cc(ccc2Br)C(F)(F)F)n1 Chemical compound Cc1nnn(Cc2cc(ccc2Br)C(F)(F)F)n1 VDGCFTQOYQKIFX-UHFFFAOYSA-N 0.000 description 1
- FOVBNKYAZCUMAB-NGQRKOQKSA-N ClC1=CC(=C(C=C1)/C=C/C(=O)OCC)CN1N=C(N=N1)C.ClC1=CC(=C(C=C1)/C=C/C(=O)O)CN1N=C(N=N1)C Chemical compound ClC1=CC(=C(C=C1)/C=C/C(=O)OCC)CN1N=C(N=N1)C.ClC1=CC(=C(C=C1)/C=C/C(=O)O)CN1N=C(N=N1)C FOVBNKYAZCUMAB-NGQRKOQKSA-N 0.000 description 1
- IIIQSJYVBPFCKH-UHFFFAOYSA-N ClC1=CC(=C(C=C1)C(C(=O)O)=C)CN1N=C(N=N1)C Chemical compound ClC1=CC(=C(C=C1)C(C(=O)O)=C)CN1N=C(N=N1)C IIIQSJYVBPFCKH-UHFFFAOYSA-N 0.000 description 1
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 1
- GJMUOKHTFQRJEJ-UHFFFAOYSA-N FCC=1OC=C(N1)CO.FCC=1OC=C(N1)C=O Chemical compound FCC=1OC=C(N1)CO.FCC=1OC=C(N1)C=O GJMUOKHTFQRJEJ-UHFFFAOYSA-N 0.000 description 1
- VXNOHILOXANPKR-UHFFFAOYSA-N FCCC1=CC=CC(=C1)C1=CC=C(C=C1)C Chemical compound FCCC1=CC=CC(=C1)C1=CC=C(C=C1)C VXNOHILOXANPKR-UHFFFAOYSA-N 0.000 description 1
- ACRBUNAECCJQEU-JREFPRNKSA-N FCCOC=1C=CC(=NC=1)CN1C[C@H](N(CC1)C(\C=C\C1=C(C=C(C=C1)O[11CH3])CN1N=C(N=N1)C)=O)C Chemical compound FCCOC=1C=CC(=NC=1)CN1C[C@H](N(CC1)C(\C=C\C1=C(C=C(C=C1)O[11CH3])CN1N=C(N=N1)C)=O)C ACRBUNAECCJQEU-JREFPRNKSA-N 0.000 description 1
- GHOMXSBNCHQXIX-FLGNKGROSA-N FCCOC=1C=CC(=NC=1)CN1C[C@H](N(CC1)C(\C=C\C1=C(C=C(C=C1)[Sn](CCCC)(CCCC)CCCC)CN1N=C(N=N1)C)=O)C Chemical compound FCCOC=1C=CC(=NC=1)CN1C[C@H](N(CC1)C(\C=C\C1=C(C=C(C=C1)[Sn](CCCC)(CCCC)CCCC)CN1N=C(N=N1)C)=O)C GHOMXSBNCHQXIX-FLGNKGROSA-N 0.000 description 1
- UCTGWJXDPWLDMD-UHFFFAOYSA-N FCCOCCOC=1C=CC(=NC1)CO.FCCOCCOC=1C=CC(=NC1)C=O Chemical compound FCCOCCOC=1C=CC(=NC1)CO.FCCOCCOC=1C=CC(=NC1)C=O UCTGWJXDPWLDMD-UHFFFAOYSA-N 0.000 description 1
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 1
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 1
- 102100036076 Glycerophosphocholine cholinephosphodiesterase ENPP6 Human genes 0.000 description 1
- 239000007821 HATU Substances 0.000 description 1
- 102100031415 Hepatic triacylglycerol lipase Human genes 0.000 description 1
- 208000017604 Hodgkin disease Diseases 0.000 description 1
- 208000021519 Hodgkin lymphoma Diseases 0.000 description 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000876254 Homo sapiens Glycerophosphocholine cholinephosphodiesterase ENPP6 Proteins 0.000 description 1
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 description 1
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- 108020002496 Lysophospholipase Proteins 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- QJGQUHMNIGDVPM-BJUDXGSMSA-N Nitrogen-13 Chemical compound [13N] QJGQUHMNIGDVPM-BJUDXGSMSA-N 0.000 description 1
- 102100039306 Nucleotide pyrophosphatase Human genes 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 108010009413 Pyrophosphatases Proteins 0.000 description 1
- 102000009609 Pyrophosphatases Human genes 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- IGLNJRXAVVLDKE-OIOBTWANSA-N Rubidium-82 Chemical compound [82Rb] IGLNJRXAVVLDKE-OIOBTWANSA-N 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- FIOOPTNDJGMGET-ZHACJKMWSA-N [(E)-2-fluoroethenyl] 4-(4-methylphenyl)benzenesulfonate Chemical compound CC1=CC=C(C=C1)C1=CC=C(C=C1)S(=O)(=O)O\C=C\F FIOOPTNDJGMGET-ZHACJKMWSA-N 0.000 description 1
- RNSDKDAOGWJATI-UHFFFAOYSA-N [2-(fluoromethyl)-1,3-oxazol-4-yl]methanol Chemical compound FCC=1OC=C(N=1)CO RNSDKDAOGWJATI-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- KXKVLQRXCPHEJC-UHFFFAOYSA-N acetic acid trimethyl ester Natural products COC(C)=O KXKVLQRXCPHEJC-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 239000012300 argon atmosphere Substances 0.000 description 1
- 150000004945 aromatic hydrocarbons Chemical class 0.000 description 1
- 125000003609 aryl vinyl group Chemical group 0.000 description 1
- YCOXTKKNXUZSKD-UHFFFAOYSA-N as-o-xylenol Natural products CC1=CC=C(O)C=C1C YCOXTKKNXUZSKD-UHFFFAOYSA-N 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 239000012131 assay buffer Substances 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- XTKDAFGWCDAMPY-UHFFFAOYSA-N azaperone Chemical compound C1=CC(F)=CC=C1C(=O)CCCN1CCN(C=2N=CC=CC=2)CC1 XTKDAFGWCDAMPY-UHFFFAOYSA-N 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- IXAOIONEQLABDS-OAHLLOKOSA-N benzyl (2R)-4-[(5-hydroxypyridin-2-yl)methyl]-2-methylpiperazine-1-carboxylate Chemical compound OC=1C=CC(=NC=1)CN1C[C@H](N(CC1)C(=O)OCC1=CC=CC=C1)C IXAOIONEQLABDS-OAHLLOKOSA-N 0.000 description 1
- KKBYAYOFCRJQQT-LLVKDONJSA-N benzyl (2r)-2-methylpiperazine-1-carboxylate Chemical compound C[C@@H]1CNCCN1C(=O)OCC1=CC=CC=C1 KKBYAYOFCRJQQT-LLVKDONJSA-N 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000008236 biological pathway Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- QHXLIQMGIGEHJP-UHFFFAOYSA-N boron;2-methylpyridine Chemical compound [B].CC1=CC=CC=N1 QHXLIQMGIGEHJP-UHFFFAOYSA-N 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 230000005587 bubbling Effects 0.000 description 1
- OKTJSMMVPCPJKN-BJUDXGSMSA-N carbon-11 Chemical compound [11C] OKTJSMMVPCPJKN-BJUDXGSMSA-N 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 230000012292 cell migration Effects 0.000 description 1
- 230000009087 cell motility Effects 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 150000001793 charged compounds Chemical class 0.000 description 1
- 238000000451 chemical ionisation Methods 0.000 description 1
- 239000013626 chemical specie Substances 0.000 description 1
- VDQQXEISLMTGAB-UHFFFAOYSA-N chloramine T Chemical compound [Na+].CC1=CC=C(S(=O)(=O)[N-]Cl)C=C1 VDQQXEISLMTGAB-UHFFFAOYSA-N 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- DOBRDRYODQBAMW-UHFFFAOYSA-N copper(i) cyanide Chemical compound [Cu+].N#[C-] DOBRDRYODQBAMW-UHFFFAOYSA-N 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 238000007333 cyanation reaction Methods 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 229940039227 diagnostic agent Drugs 0.000 description 1
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 1
- 235000011180 diphosphates Nutrition 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 238000000132 electrospray ionisation Methods 0.000 description 1
- 230000013020 embryo development Effects 0.000 description 1
- 231100001129 embryonic lethality Toxicity 0.000 description 1
- VFRSADQPWYCXDG-LEUCUCNGSA-N ethyl (2s,5s)-5-methylpyrrolidine-2-carboxylate;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.CCOC(=O)[C@@H]1CC[C@H](C)N1 VFRSADQPWYCXDG-LEUCUCNGSA-N 0.000 description 1
- USRMOSOONWAMRT-FNORWQNLSA-N ethyl (E)-3-[2-[(5-methyltetrazol-2-yl)methyl]-4-(trifluoromethyl)phenyl]prop-2-enoate Chemical compound CCOC(=O)\C=C\c1ccc(C(F)(F)F)cc1Cn1nnc(C)n1 USRMOSOONWAMRT-FNORWQNLSA-N 0.000 description 1
- NHSKZEDWMSBGBY-FNORWQNLSA-N ethyl (E)-3-[4-chloro-2-[(5-methyltetrazol-2-yl)methyl]phenyl]prop-2-enoate Chemical compound CCOC(=O)\C=C\c1ccc(Cl)cc1Cn1nnc(C)n1 NHSKZEDWMSBGBY-FNORWQNLSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 description 1
- 201000003444 follicular lymphoma Diseases 0.000 description 1
- 230000005251 gamma ray Effects 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 238000002290 gas chromatography-mass spectrometry Methods 0.000 description 1
- 238000003209 gene knockout Methods 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
- 125000005842 heteroatom Chemical group 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 238000011503 in vivo imaging Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 208000036971 interstitial lung disease 2 Diseases 0.000 description 1
- SNHMUERNLJLMHN-UHFFFAOYSA-N iodobenzene Chemical compound IC1=CC=CC=C1 SNHMUERNLJLMHN-UHFFFAOYSA-N 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 201000010982 kidney cancer Diseases 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- XIXADJRWDQXREU-UHFFFAOYSA-M lithium acetate Chemical compound [Li+].CC([O-])=O XIXADJRWDQXREU-UHFFFAOYSA-M 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 238000002595 magnetic resonance imaging Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- CMUKPCIZFMTLKD-UHFFFAOYSA-N methyl 2-(chloromethyl)-1,3-oxazole-4-carboxylate Chemical compound COC(=O)C1=COC(CCl)=N1 CMUKPCIZFMTLKD-UHFFFAOYSA-N 0.000 description 1
- JMABHJSYSMFHKQ-UHFFFAOYSA-N methyl 2-(fluoromethyl)-1,3-oxazole-4-carboxylate Chemical compound COC(=O)C1=COC(CF)=N1 JMABHJSYSMFHKQ-UHFFFAOYSA-N 0.000 description 1
- AWUPLMYXZJKHEG-UHFFFAOYSA-N methyl 2-chloro-2,2-difluoroacetate Chemical compound COC(=O)C(F)(F)Cl AWUPLMYXZJKHEG-UHFFFAOYSA-N 0.000 description 1
- 230000001035 methylating effect Effects 0.000 description 1
- 230000004899 motility Effects 0.000 description 1
- ULWOJODHECIZAU-UHFFFAOYSA-N n,n-diethylpropan-2-amine Chemical compound CCN(CC)C(C)C ULWOJODHECIZAU-UHFFFAOYSA-N 0.000 description 1
- JFTRZKNANMCEJJ-HWKANZROSA-N n1c(C)nnn1Cc1cc(C(F)(F)F)ccc1\C=C\C(O)=O Chemical compound n1c(C)nnn1Cc1cc(C(F)(F)F)ccc1\C=C\C(O)=O JFTRZKNANMCEJJ-HWKANZROSA-N 0.000 description 1
- XDZYLPRSNSGZFC-SNAWJCMRSA-N n1c(C)nnn1Cc1cc(C(F)F)ccc1\C=C\C(O)=O Chemical compound n1c(C)nnn1Cc1cc(C(F)F)ccc1\C=C\C(O)=O XDZYLPRSNSGZFC-SNAWJCMRSA-N 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 238000002414 normal-phase solid-phase extraction Methods 0.000 description 1
- 238000012633 nuclear imaging Methods 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 108010027581 nucleoside triphosphate pyrophosphatase Proteins 0.000 description 1
- 108010067588 nucleotide pyrophosphatase Proteins 0.000 description 1
- 125000002811 oleoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])/C([H])=C([H])\C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- LVSJDHGRKAEGLX-UHFFFAOYSA-N oxolane;2,2,2-trifluoroacetic acid Chemical compound C1CCOC1.OC(=O)C(F)(F)F LVSJDHGRKAEGLX-UHFFFAOYSA-N 0.000 description 1
- QVGXLLKOCUKJST-BJUDXGSMSA-N oxygen-15 atom Chemical compound [15O] QVGXLLKOCUKJST-BJUDXGSMSA-N 0.000 description 1
- LXNAVEXFUKBNMK-UHFFFAOYSA-N palladium(II) acetate Substances [Pd].CC(O)=O.CC(O)=O LXNAVEXFUKBNMK-UHFFFAOYSA-N 0.000 description 1
- YJVFFLUZDVXJQI-UHFFFAOYSA-L palladium(ii) acetate Chemical compound [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 239000003880 polar aprotic solvent Substances 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 238000000163 radioactive labelling Methods 0.000 description 1
- 238000003653 radioligand binding assay Methods 0.000 description 1
- 238000006268 reductive amination reaction Methods 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 230000016160 smooth muscle contraction Effects 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 239000011877 solvent mixture Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- KXCAEQNNTZANTK-UHFFFAOYSA-N stannane Chemical compound [SnH4] KXCAEQNNTZANTK-UHFFFAOYSA-N 0.000 description 1
- 229910000080 stannane Inorganic materials 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- LECUHBWLJZLSBT-LOWQCSRCSA-N tert-butyl (3R)-3-methyl-4-[(E)-3-[2-[(5-methyltetrazol-2-yl)methyl]-4-(trifluoromethyl)phenyl]prop-2-enoyl]piperazine-1-carboxylate Chemical compound C[C@@H]1CN(CCN1C(\C=C\C1=C(C=C(C=C1)C(F)(F)F)CN1N=C(N=N1)C)=O)C(=O)OC(C)(C)C LECUHBWLJZLSBT-LOWQCSRCSA-N 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 229960001479 tosylchloramide sodium Drugs 0.000 description 1
- 102000035160 transmembrane proteins Human genes 0.000 description 1
- 108091005703 transmembrane proteins Proteins 0.000 description 1
- PIILXFBHQILWPS-UHFFFAOYSA-N tributyltin Chemical compound CCCC[Sn](CCCC)CCCC PIILXFBHQILWPS-UHFFFAOYSA-N 0.000 description 1
- 238000006692 trifluoromethylation reaction Methods 0.000 description 1
- 238000001946 ultra-performance liquid chromatography-mass spectrometry Methods 0.000 description 1
- 238000000825 ultraviolet detection Methods 0.000 description 1
- 239000003039 volatile agent Substances 0.000 description 1
- 238000005945 von Braun degradation reaction Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B6/00—Apparatus or devices for radiation diagnosis; Apparatus or devices for radiation diagnosis combined with radiation therapy equipment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B8/00—Diagnosis using ultrasonic, sonic or infrasonic waves
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/041—Heterocyclic compounds
- A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/041—Heterocyclic compounds
- A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K51/0459—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/002—Heterocyclic compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Optics & Photonics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medical Informatics (AREA)
- Engineering & Computer Science (AREA)
- Surgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pathology (AREA)
- Radiology & Medical Imaging (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- High Energy & Nuclear Physics (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Enzymes And Modification Thereof (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Nuclear Medicine (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562105336P | 2015-01-20 | 2015-01-20 | |
| US62/105,336 | 2015-01-20 | ||
| PCT/IB2016/050276 WO2016116875A1 (en) | 2015-01-20 | 2016-01-20 | Pet imaging agents |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020106739A Division JP2020158532A (ja) | 2015-01-20 | 2020-06-22 | Ｐｅｔイメージング剤 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018511648A JP2018511648A (ja) | 2018-04-26 |
| JP2018511648A5 JP2018511648A5 (enExample) | 2019-02-21 |
| JP6723264B2 true JP6723264B2 (ja) | 2020-07-15 |
Family
ID=55300733
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017555866A Expired - Fee Related JP6723264B2 (ja) | 2015-01-20 | 2016-01-20 | Ｐｅｔイメージング剤 |
| JP2020106739A Pending JP2020158532A (ja) | 2015-01-20 | 2020-06-22 | Ｐｅｔイメージング剤 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020106739A Pending JP2020158532A (ja) | 2015-01-20 | 2020-06-22 | Ｐｅｔイメージング剤 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US10450298B2 (enExample) |
| EP (1) | EP3247706B1 (enExample) |
| JP (2) | JP6723264B2 (enExample) |
| KR (1) | KR20170103960A (enExample) |
| CN (1) | CN107406419B (enExample) |
| AU (1) | AU2016209906A1 (enExample) |
| BR (1) | BR112017015455A2 (enExample) |
| CA (1) | CA2974311A1 (enExample) |
| EA (1) | EA201791643A1 (enExample) |
| ES (1) | ES2828715T3 (enExample) |
| MX (1) | MX2017009452A (enExample) |
| WO (1) | WO2016116875A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2974311A1 (en) | 2015-01-20 | 2016-07-28 | Novartis Ag | Pet imaging agents |
| TWI809597B (zh) * | 2020-12-16 | 2023-07-21 | 美商美國禮來大藥廠 | 預靶向造影劑 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0224917D0 (en) * | 2002-10-25 | 2002-12-04 | Novartis Ag | Organic compounds |
| WO2005043300A2 (en) | 2003-10-20 | 2005-05-12 | Empirix, Inc. | Computer language interpretation and optimization for server testing |
| BRPI0510512A (pt) | 2004-04-28 | 2007-10-30 | Icos Corp | derivados de arilfenilamino, arilfenilamida e sulfeto de arilfeniléter |
| WO2005121094A1 (en) | 2004-06-09 | 2005-12-22 | Pfizer Limited | Piperazine and piperidine derivatives as anti-hiv-agents |
| CN101429161A (zh) * | 2008-12-05 | 2009-05-13 | 常熟理工学院 | Pet显像剂前体异喹啉甲酰胺衍生物的合成方法 |
| JP5767205B2 (ja) * | 2009-04-02 | 2015-08-19 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ | オートタキシン阻害剤としての複素環式化合物 |
| US8999974B2 (en) | 2010-08-09 | 2015-04-07 | Raqualia Pharma Inc. | Acyl piperazine derivatives as TTX-S blockers |
| JP2013536200A (ja) * | 2010-08-20 | 2013-09-19 | アミラ ファーマシューティカルス，インコーポレーテッド | オートタキシン阻害剤およびその使用 |
| PT2861566T (pt) * | 2012-06-13 | 2017-02-08 | Hoffmann La Roche | Novos diazaspirocicloalcanos e azaspirocicloalcanos |
| CN104968656B (zh) * | 2012-12-19 | 2017-08-11 | 诺华股份有限公司 | 自分泌运动因子抑制剂 |
| SG11201600241RA (en) | 2013-07-18 | 2016-02-26 | Novartis Ag | Autotaxin inhibitors comprising a heteroaromatic ring-benzyl-amide-cycle core |
| CA2974311A1 (en) | 2015-01-20 | 2016-07-28 | Novartis Ag | Pet imaging agents |
-
2016
- 2016-01-20 CA CA2974311A patent/CA2974311A1/en not_active Withdrawn
- 2016-01-20 EP EP16702985.9A patent/EP3247706B1/en active Active
- 2016-01-20 MX MX2017009452A patent/MX2017009452A/es unknown
- 2016-01-20 CN CN201680016753.9A patent/CN107406419B/zh active Active
- 2016-01-20 ES ES16702985T patent/ES2828715T3/es active Active
- 2016-01-20 KR KR1020177022757A patent/KR20170103960A/ko not_active Withdrawn
- 2016-01-20 JP JP2017555866A patent/JP6723264B2/ja not_active Expired - Fee Related
- 2016-01-20 US US15/544,850 patent/US10450298B2/en active Active
- 2016-01-20 EA EA201791643A patent/EA201791643A1/ru unknown
- 2016-01-20 BR BR112017015455-2A patent/BR112017015455A2/pt not_active Application Discontinuation
- 2016-01-20 WO PCT/IB2016/050276 patent/WO2016116875A1/en not_active Ceased
- 2016-01-20 AU AU2016209906A patent/AU2016209906A1/en not_active Abandoned
-
2019
- 2019-09-24 US US16/581,086 patent/US10865195B2/en active Active
-
2020
- 2020-06-22 JP JP2020106739A patent/JP2020158532A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN107406419A (zh) | 2017-11-28 |
| US20200017474A1 (en) | 2020-01-16 |
| US20180273509A1 (en) | 2018-09-27 |
| EA201791643A1 (ru) | 2017-11-30 |
| EP3247706A1 (en) | 2017-11-29 |
| MX2017009452A (es) | 2017-11-08 |
| US10450298B2 (en) | 2019-10-22 |
| AU2016209906A1 (en) | 2017-08-03 |
| EP3247706B1 (en) | 2020-07-08 |
| KR20170103960A (ko) | 2017-09-13 |
| ES2828715T3 (es) | 2021-05-27 |
| CA2974311A1 (en) | 2016-07-28 |
| BR112017015455A2 (pt) | 2018-01-23 |
| US10865195B2 (en) | 2020-12-15 |
| CN107406419B (zh) | 2020-09-11 |
| CN107406419A8 (zh) | 2018-01-12 |
| JP2018511648A (ja) | 2018-04-26 |
| JP2020158532A (ja) | 2020-10-01 |
| WO2016116875A1 (en) | 2016-07-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6224063B2 (ja) | ホスホジエステラーゼ１−標的トレーサーおよび方法 | |
| JP2016056184A5 (enExample) | ||
| JP7752201B2 (ja) | 放射性標識カンナビノイド受容体２リガンド | |
| JP2014074029A (ja) | 神経学的障害を検知するためのイメージング剤 | |
| EP4028402A1 (en) | Radiolabeled compounds | |
| Poot et al. | [11C] Sorafenib: Radiosynthesis and preclinical evaluation in tumor-bearing mice of a new TKI-PET tracer | |
| BRPI0808503B1 (pt) | Composto, uso de um composto, e, composição farmacêutica | |
| US10865195B2 (en) | Pet imaging agents | |
| JP6840666B2 (ja) | 新規なアントラニル酸誘導体 | |
| Sai et al. | Development of 18F-labeled PET probes for imaging cell proliferation | |
| JP6609868B2 (ja) | 放射性ハロゲン標識ピリド［１，２−ａ］ベンゾイミダゾール誘導体化合物 | |
| JP6994715B2 (ja) | Ｂｃｒ－Ａｂｌタンパク質イメージング用分子プローブ | |
| JP2009132701A (ja) | 核医学診断用医薬 | |
| JP6709552B2 (ja) | 核医学画像診断薬 | |
| JP7024960B2 (ja) | Ｂｃｒ－Ａｂｌタンパク質イメージング用分子プローブ | |
| JP6739987B2 (ja) | 核医学画像診断薬 | |
| FAWWAZ | Development of radiolabeled probes for the prediction of therapeutic effects of EGFR-tyrosine kinase inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20190108 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20190108 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20191001 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20191003 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20191227 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200123 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20200526 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20200623 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6723264 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| LAPS | Cancellation because of no payment of annual fees |